Asston Pharmaceuticals IPO Details
The Asston Pharmaceuticals IPO is a book build issue with a total issue size of ₹27.56 cr, comprising of fresh issue of 2241000 equity shares. Asston Pharmaceuticals IPO opened for subscription on Jul 09, 2025 and closed on Jul 11, 2025. Asston Pharmaceuticals IPO is set price band at ₹115 to ₹123 per share, with a lot size of 1000 shares. Minimum investment for Retail investors was ₹246,000.00 (at the upper price band) to apply for one lot.
The basis of allotment got finalized on Jul 14, 2025, and listed on both the NSE and BSE on Jul 16, 2025.
Maashitla Securities Pvt. Limited has been appointed as the registrar. Sobhagya Capital Options Ltd are the Book Running Lead Manager for the issue.
Before investing in the Asston Pharmaceuticals IPO, investors should review the company's financial performance, business objectives, and risk factors mentioned in the offer documents and apply before the subscription window closes.
- Price Band
- ₹ 115 – 123
- Lot Size
- 1000
- Issue Size
- ₹27.56 Cr
- Minimum Investment
- ₹246000 (2000 Shares)
- Listing Date
- 16 July 2025
Current GMP
₹26 (+21.14%)
*Info is indicative. Not an Investment Advice. Grey market trading is unregulated.
About Asston Pharmaceuticals Limited
Asston Pharmaceuticals Limited is an Indian pharmaceutical and nutraceutical manufacturer and exporter operating under the brand name “Asston”. The company primarily caters to domestic and African markets, focusing on affordable, high-quality formulations.
Core Operations:
- Product Categories: Tablets, Capsules, Syrups, Oral Powders (Sachets, Dry Syrups), External Preparations (Ointments, Creams, Gels, Lotions), Injectables (LVP & SVP).
- Business Model:
- Direct manufacturing and marketing.
- Contract manufacturing and loan licensing for corporate clients.
- Production Facility: Located in Ambernath, Maharashtra, with separate floors for:
- Pharmaceuticals (FDA-governed)
- Nutraceuticals (FSSAI-governed)
Manufacturing Capabilities:
- Tablets: Capacity of 8–9 crore tablets/month; average production 5–6 crore/month.
- Syrups (Nutraceuticals): ~37.5 kiloliters/month.
- Sachets: 30–40 lakh/month (depending on weight).
- Facility includes QA/QC labs, warehouse, and is FDA-certified (Central and State) and NQA-accredited.
Quality and Regulatory Compliance:
- WHO-GMP certified contract manufacturers.
- Own regulatory department and tie-ups with NABL-accredited labs.
- Complies with Quality Management System (QMS) standards.
- Operations fall under green and orange environmental zones.
- Over 150 registered trademarks for formulations.
Products and Markets:
- Broad range includes generic medicines, pediatric drugs, eye drops, NTTB (New to the Basket) treatments.
- Distributed across more than 10 countries, including South Africa and West Africa.
- Focus on price-sensitive markets with low-cost, quality formulations.
Growth and Development:
- Founded: April 16, 2019, as a private limited company.
- Acquired Ferron Lifecare’s nutraceutical plant in Ambernath in April 2024.
- Converted to a public limited company on August 29, 2024.
- FDA approval for pharmaceutical manufacturing received on December 2, 2024.
- Leadership Team: Dr. Ashish Sakalkar, Mrs. Saili More, and Mr. Sachin Badakh.
- Team Size: 50+ employees and expanding.
Strategic Initiatives:
- 5-year contracts with WHO-GMP-certified manufacturers for various formulations.
- Ongoing expansion with a new loan license deal in Gujarat for ointment production.
- In-house regulatory team supports dossier preparation and global compliance for exports.
Asston Pharmaceuticals IPO Promoters
- Dr. Ashish Narayan Sakalkar
- Saili Jayaram More
- Sachin Chandrakant Badakh
Promoters Holding
Holding Pre Issue
68.76%
Holding Post Issue
50.66%
Asston Pharmaceuticals IPO Objective
The Company Asston Pharmaceuticals IPO proposes to utilise the Net Proceeds from the Issue towards the following objects:
- Funding capital expenditure requirements towards acquiring machinery in the manufacturing unit
- Funding the incremental working capital requirements of the Company
- Repayment and/or prepayment, in part or full, of certain of the outstanding borrowings availed by the Company
- General Corporate Purposes
Address / Contact Info
Asston Pharmaceuticals Limited
4th Floor, Office No. A-431 Balaji Bhavan,
Plot No 42A Sector-11 CBD Belapur,
Navi Mumbai, Thane
Navi Mumbai, Maharashtra, 400614
Phone: +91 22 49731411
Email: info@asstonpharmaceuticals.com
Website: http://www.asstonpharmaceuticals.com/
IPO Snapshot
Book Running Lead Managers
- Sobhagya Capital Options Ltd
Disclaimer: This data is for informational purposes only and does not constitute investment advice. Figures shown are illustrative sample data.
Frequently Asked Questions
Everything you need to know before applying to an IPO.
Asston Pharmaceuticals IPO is a Book-building IPO with a total issue size of ₹27.56 crore. The Asston Pharmaceuticals IPO price band is ₹115 to 123 per share. The Asston Pharmaceuticals IPO subscription opens on Wed, Jul 9, 2025, and closes on Fri, Jul 11, 2025. The Asston Pharmaceuticals IPO will be listed on the BSE. Maashitla Securities Pvt. Limited is the registrar for the Asston Pharmaceuticals IPO.
The Asston Pharmaceuticals IPO opens on Wed, Jul 9, 2025 and closes on Fri, Jul 11, 2025
Asston Pharmaceuticals IPO Price Band is ₹115 to 123 per share.
Asston Pharmaceuticals IPO lot size is 1000 shares, Retail investors need a minimum investment of ₹246000 based on the upper price band
The minimum investment for Asston Pharmaceuticals IPO is ₹246000, based on one lot of 1000 shares at the upper price band of ₹123 per share.
Investors can apply for the Asston Pharmaceuticals IPO through the ASBA (Application Supported by Blocked Amount) facility offered by their bank or through UPI using a SEBI-registered broker or trading app. Select the desired lot size, enter your bid within the price band, and submit the application before Fri, Jul 11, 2025. The application amount remains blocked until the Asston Pharmaceuticals IPO allotment is finalized.
Asston Pharmaceuticals IPO issue size is ₹27.56 crores.
Asston Pharmaceuticals IPO allotment date is Wed, Jul 1, 2026.
The registrar for Asston Pharmaceuticals IPO is Maashitla Securities Pvt. Limited. Investors can go to Maashitla Securities Pvt. Limited website to check Asston Pharmaceuticals IPO allotment status, refund processing, and other IPO-related information.
The Asston Pharmaceuticals IPO GMP (Grey Market Premium) is ₹26 as of Wed, Jul 16, 2025. Based on the upper price band of ₹123 per share, the estimated Asston Pharmaceuticals IPO listing price is ₹149, indicating a potential listing gain of approximately 0% over the issue price.